VANCOUVER, Jan. 28, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAW, TXD: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today the Executive Steering Committee for its fully retrievable transfemoral trans-septal Tiara™ (“TF/TS Tiara”) program. The Company intends to enroll the first patient in a feasibility trial in late 2020, pending achievement of development and regulatory milestones.
The Executive Steering Committee is comprised of:
— Anson Cheung, M.D., Cardiac Surgeon, St Paul’s Hospital, Vancouver, B.C., Canada — Lenard Conradi, M.D., Cardiac Surgeon, University Heart Center, Hamburg, Germany — Ulrich Schaefer, M.D., Interventional Cardiologist, Marien Krankenhaus, Hamburg, Germany — Paul Sorajja, M.D., Interventional Cardiologist, Minneapolis Heart Institute, Minneapolis, MN, U.S.A — Stephen Worthley, M.D., Interventional Cardiologist, Genesis Heathcare, Sydney, Australia — Shmuel Banai, M.D., Medical Director, Neovasc and Interventional Cardiologist, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Click here to read the full story on Associated Press.
Similar story can be found in the following media outlet: Yahoo Finance